81724

ACOSOG Z1041 (Alliance): Definitive Analysis of  Randomized Neoadjuvant Trial Comparing FEC Followed by Paclitaxel Plus Trastuzumab (FEC - P+T) with Paclitaxel Plus Trastuzumab Followed by FEC Plus Trastuzumab (P+T - FEC+T) in HER2+ Operable Breast Cancer.


More by Aman Buzdar :